// App-Quantinova.ai

: Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD

Researchers

Presenter

  • Ian Douglas Pavord

Principal Investigators

  • Huib A M Kerstjens

  • Stephanie Korn

  • Gerard J Criner

  • Hironori Sagara

  • David B Rubin

  • Stephanie Schweiker Harris

  • Bhabita Mayer

  • Eric S Bradford

  • Frank C Albers

  • Steven W Yancey

Medical Centers

  • Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom,

  • Dept. of Pulmonary Diseases - University of Groningen and University Medical Center Groningen, Groningen, Netherlands

  • Pulmonary Department, III. Medical Department, Mainz University Hospital, Mainz, Germany

  • Pulmonary and Critical Care Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, United States of America

  • Allergology & Respiratory Medicine, Showa University School of Medicine, Tokyo, Japan

  • Respiratory Therapeutic Area, GSK, Research Triangle Park, North Carolina, United States of America

  • Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, United Kingdom,

  • Respiratory Medical Franchise, GSK, Research Triangle Park, NC, United States,

Locations

  • United Kingdom

  • Netherlands

  • Germany

  • United States

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Controlled

  • Parallel Group

Phase

  • III

Study Id's

  • NCT02105961

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved